^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Lipusu (liposomal paclitaxel)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Luye Group
Drug class:
Bcl2 inhibitor, Tubulin inhibitor
Related drugs:
over2years
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. (PubMed, Cancer Commun (Lond))
The LP regimen demonstrated similar PFS, OS, ORR and DCR as the GP regimen for patients with locally advanced or metastatic LSCC but had more favorable toxicity profiles. The study also identified a spectrum of different cytokines that could be potentially associated with the clinical benefit in patients who received the LP regimen.
Clinical • Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
gemcitabine • Lipusu (liposomal paclitaxel)
Share via
